The demand for the fast and robust development of manufacturing cell lines is ever growing, with an increasing number of therapeutic proteins in development. To fulfill these needs, Celonic engineered the cell line kit CHOvolution, which equips users with everything required for the development of mammalian cell lines and provides an integrated support system for assistance.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_2018_celonic1.png5981060Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-10-12 06:00:002024-04-02 16:21:08Cutting time to market for high quality therapeutics
Six years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.
https://european-biotechnology.com/wp-content/uploads/2024/04/Katainen.jpg454639Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-10-12 05:38:002018-10-12 05:38:00EU set to speed up switch to bioeconomy by new action plan
Genentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I trails.
https://european-biotechnology.com/wp-content/uploads/2024/04/AFFIMED.jpg6561373Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-10-10 08:11:232018-10-10 08:11:23Affimed halts trial after patient death and SAEs
Aglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_stevendocksey.jpg400400h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-10-09 16:50:272018-10-09 16:50:27Aglaris Appoints New CEO
The Innovative Medicines Initiative 2 (IMI2) has launched a new Antimicrobial Resistance Accelerator Programme following on the heels of its outgoing NewDrugs4BadBugs programme.
Oxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and GlaxoSmithKline plc participated in this financing.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cell_Metabolism.jpg19902250Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-10-09 05:29:182018-10-09 05:29:18Sitryx Therapeutics bags $30m in Series A Financing
Exscientia, a company in Artificial Intelligence (AI)-driven drug discovery, has announced the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO).
British gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow to balance its costs, which rose from US$13m to US$138m this year. Financial markets are expected to react positively.
Diagnostics company sphingotec GmbH successfully closed a €20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.
Cutting time to market for high quality therapeutics
BackgroundThe demand for the fast and robust development of manufacturing cell lines is ever growing, with an increasing number of therapeutic proteins in development. To fulfill these needs, Celonic engineered the cell line kit CHOvolution, which equips users with everything required for the development of mammalian cell lines and provides an integrated support system for assistance.
EU set to speed up switch to bioeconomy by new action plan
Latest NewsSix years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.
Bacterial antigen mimicry drives MS
Latest NewsT cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).
Affimed halts trial after patient death and SAEs
Latest NewsGenentech’s new partner Affimed NV has halted two blood cancer programmes with its tetravalent bispecific T cell engager AFM11 after a death and two cases of severe neurotoxicity occured in Phase I trails.
Aglaris Appoints New CEO
AppointmentsAglaris Ltd. yesterday announced the appointment of Steven Docksey to the role of CEO of the Anglo-Spanish cell therapy equipment manufacturer, effective immediately.
IMI fosters antibiotics research amidst Big Pharma pullbacks
BackgroundThe Innovative Medicines Initiative 2 (IMI2) has launched a new Antimicrobial Resistance Accelerator Programme following on the heels of its outgoing NewDrugs4BadBugs programme.
Sitryx Therapeutics bags $30m in Series A Financing
Latest NewsOxford-based immunoncology player Sitryx Therapeutics Ltd. (Oxford, U.K.) has bagged $30m in a Series A financing round led by SV Health Investors and new investor Sofinnova Partners. Longwood Fund and GlaxoSmithKline plc participated in this financing.
Exscientia Appoints Georgy Egorov as CFO
AppointmentsExscientia, a company in Artificial Intelligence (AI)-driven drug discovery, has announced the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO).
Orchard plans to raise US$172m in ADS
Latest NewsBritish gene therapy developer Orchard Therapeutics will go IPO on Nasdaq, according to SEC filings. The company plans to raise $172.5m as ADS in an IPO underwritten by J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow to balance its costs, which rose from US$13m to US$138m this year. Financial markets are expected to react positively.
Sphingotec raises €20m in growth equity financing
Latest NewsDiagnostics company sphingotec GmbH successfully closed a €20m growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners.